WO2014165082A3 - Antibodies and methods of detection - Google Patents

Antibodies and methods of detection Download PDF

Info

Publication number
WO2014165082A3
WO2014165082A3 PCT/US2014/024331 US2014024331W WO2014165082A3 WO 2014165082 A3 WO2014165082 A3 WO 2014165082A3 US 2014024331 W US2014024331 W US 2014024331W WO 2014165082 A3 WO2014165082 A3 WO 2014165082A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
detection
disclosed
antibody fragments
Prior art date
Application number
PCT/US2014/024331
Other languages
French (fr)
Other versions
WO2014165082A2 (en
Inventor
Mark Julian AUSTIN
Arthur Richard LEWIS
Paul Brian ROBBINS
Marlon Cezar REBELATTO
Charles Robert BROWN II
Theresa Marie LAVALLEE
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of WO2014165082A2 publication Critical patent/WO2014165082A2/en
Publication of WO2014165082A3 publication Critical patent/WO2014165082A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are methods for detecting surface expressed proteins, for example, B7 family members such as PD-L1. Also disclosed are antibodies and antibody fragments that specifically bind PD-L1 and methods for generating antibodies and antibody fragments that specifically bind PD-L1.
PCT/US2014/024331 2013-03-13 2014-03-12 Antibodies and methods of detection WO2014165082A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779423P 2013-03-13 2013-03-13
US61/779,423 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014165082A2 WO2014165082A2 (en) 2014-10-09
WO2014165082A3 true WO2014165082A3 (en) 2015-03-19

Family

ID=51659315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024331 WO2014165082A2 (en) 2013-03-13 2014-03-12 Antibodies and methods of detection

Country Status (1)

Country Link
WO (1) WO2014165082A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111363041B (en) * 2016-03-23 2022-02-22 苏州创胜医药集团有限公司 Novel anti-PD-L1 antibodies

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3633377A1 (en) 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2926856A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2947932C (en) * 2014-05-29 2021-03-30 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
EP3166974A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
CN114920840A (en) 2014-10-14 2022-08-19 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
WO2016124558A1 (en) * 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MX2017011644A (en) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN116640214A (en) 2016-08-09 2023-08-25 科马布有限公司 Isolated antibodies and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN109232740B (en) * 2018-08-20 2022-05-10 中国科学院微生物研究所 anti-PD-L1 antibody and application thereof in anti-tumor treatment
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (en) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー CD71-binding fibronectin type III domain
MX2023000197A (en) 2020-07-07 2023-02-22 BioNTech SE Therapeutic rna for hpv-positive cancer.
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (en) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
US20100028330A1 (en) * 2002-12-23 2010-02-04 Medimmune Limited Methods of upmodulating adaptive immune response using anti-pd1 antibodies
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
US20110118149A1 (en) * 2009-05-20 2011-05-19 Nicolas Fischer Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants
US20130034559A1 (en) * 2009-11-24 2013-02-07 Medlmmune Limited Targeted Binding Agents Against B7-H1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028330A1 (en) * 2002-12-23 2010-02-04 Medimmune Limited Methods of upmodulating adaptive immune response using anti-pd1 antibodies
US20090176317A1 (en) * 2006-04-20 2009-07-09 Mayo Foundation For Medical Education And Research Soluble B7-H1
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
US20110118149A1 (en) * 2009-05-20 2011-05-19 Nicolas Fischer Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants
US20130034559A1 (en) * 2009-11-24 2013-02-07 Medlmmune Limited Targeted Binding Agents Against B7-H1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARRIOS, Y ET AL.: "Length Of The Antibody Heavy Chain Complementarity Determining Region 3 As A Specificity-Determining Factor.", J MOL RECOGNIT., vol. 17, no. 4, August 2004 (2004-08-01), pages 332 - 8 *
BRAUNINGER, A ET AL.: "Survival And Clonal Expansion Of Mutating ''Forbidden'' (Immunoglobulin Receptor-Deficient) Epstein-Barr Virus-Infected B Cells In Angioimmunoblastic T Cell Lymphoma.", J EXP MED., vol. 194, no. 7, 1 October 2001 (2001-10-01), pages 927 - 40 *
LONGO, N ET AL.: "Analysis Of Somatic Hypermutation In X-Linked Hyper-IgM Syndrome Shows Specific Deficiencies In Mutational Targeting.", BLOOD., vol. 113, no. 16, 16 April 2009 (2009-04-16), pages 3706 - 3715 *
SCAMURRA, R ET AL.: "Ig Heavy Chain Variable Region, VH3 Family, Partial [Homo sapiens]. Center for Biotechnology Information.", GENBANK ENTRY., 22 January 2002 (2002-01-22), Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/protein/33318912> [retrieved on 20141203] *
SCOTT, N ET AL.: "Anti-Tetanus Toxin Single-Chain Fv, Partial [Synthetic Construct]. National Center for Biotechnology Information.", GENBANK ENTRY., 3 July 2007 (2007-07-03), Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/protein/156713670> [retrieved on 20141202] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111363041B (en) * 2016-03-23 2022-02-22 苏州创胜医药集团有限公司 Novel anti-PD-L1 antibodies

Also Published As

Publication number Publication date
WO2014165082A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
WO2014165082A3 (en) Antibodies and methods of detection
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
EP3378871A4 (en) Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof
EP3060581A4 (en) Anti-pd-l1 monoclonal antibodies and fragments thereof
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EP3702372A3 (en) Anti-cd40 human antibodies
MX2017001597A (en) Anti-pd-l1 antibodies.
EA201591750A1 (en) ANTIBODIES AGAINST B7-H4 AND IMMUNOCONJUGATES
MX2015017331A (en) Anti-fcrh5 antibodies.
EP3004168A4 (en) Chimeric antigen receptor-targeting monoclonal antibodies
EA201390933A1 (en) ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES
EP3442576A4 (en) High affinity b7-h6 antibodies and antibody fragments
WO2014144865A3 (en) Anti-crth2 antibodies and their use
MX360368B (en) Modified antibody regions and uses thereof.
EP3024850A4 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
EP3038650A4 (en) Antibodies and assays for detection of folate receptor 1
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
CR20140382A (en) ANTI-LRP5 ANTIBODIES AND METHODS OF USE
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
WO2015051320A3 (en) Anti-sox10 antibody systems and methods
EP3096784A4 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
EP3054298A4 (en) Method for detecting pancreatic tumor, antibody, and pancreatic tumor detection kit
WO2014197885A3 (en) Inhibitors of complement factor h
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
SG10201807572PA (en) Robust antibody purification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14778372

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14778372

Country of ref document: EP

Kind code of ref document: A2